Skip to main content
Top
Published in: Supportive Care in Cancer 10/2021

Open Access 01-10-2021 | Original Article

Measuring quality of life in people living with and beyond cancer in the UK

Authors: Elisavet Moschopoulou, Jennifer Deane, Morvwen Duncan, Sharif A. Ismail, Sophie Moriarty, Shah-Jalal Sarker, Peter White, Ania Korszun, on behalf of the SURECAN Development Grant investigators

Published in: Supportive Care in Cancer | Issue 10/2021

Login to get access

Abstract

Purpose

The aim of this study was to identify the most appropriate measure of quality of life (QoL) for patients living with and beyond cancer.

Methods

One hundred eighty-two people attending cancer clinics in Central London at various stages post-treatment, completed a series of QoL measures: FACT-G, EORTC QLQ-C30 , IOCv2 (positive and negative subscales) and WEMWBS, a wellbeing measure. These measures were chosen as the commonest measures used in previous research. Correlation tests were used to assess the association between scales. Participants were also asked about pertinence and ease of completion.

Results

There was a significant positive correlation between the four domain scores of the two health-related QoL measures (.32 ≤ r ≤ .72, P < .001), and a significant large negative correlation between these and the negative IOCv2 subscale scores (− .39 ≤ r ≤ − .63, P < .001). There was a significant moderate positive correlation between positive IOCv2 subscale and WEMWBS scores (r = .35, P < .001). However, neither the FACT-G nor the EORTC showed any significant correlation with the positive IOCv2 subscale. Participants rated all measures similarly with regards to pertinence and ease of use.

Conclusion

There was little to choose between FACT-G, EORTC, and the negative IOC scales, any of which may be used to measure QoL. However, the two IOCv2 subscales capture unique aspects of QoL compared to the other measures. The IOCv2 can be used to identify those cancer survivors who would benefit from interventions to improve their QoL and to target specific needs thereby providing more holistic and personalised care beyond cancer treatment.
Literature
5.
go back to reference Bottomley A (2002) The cancer patient and quality of life. Oncologist 7(2):120–125CrossRef Bottomley A (2002) The cancer patient and quality of life. Oncologist 7(2):120–125CrossRef
7.
go back to reference Korszun A, Sarker SJ, Chowdhury K, Clark C, Greaves P, Johnson R, Kingston J, Levitt G, Matthews J, White P, Lister A, Gribben J (2014) Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. Br J Haematol 164(6):790–803. https://doi.org/10.1111/bjh.12698CrossRefPubMed Korszun A, Sarker SJ, Chowdhury K, Clark C, Greaves P, Johnson R, Kingston J, Levitt G, Matthews J, White P, Lister A, Gribben J (2014) Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. Br J Haematol 164(6):790–803. https://​doi.​org/​10.​1111/​bjh.​12698CrossRefPubMed
9.
go back to reference Sodergren SC, Wheelwright SJ, Permyakova NV, Patel M, Calman L, Smith PWF, Din A, Richardson A, Fenlon D, Winter J, Corner J, Foster C (2019) Supportive care needs of patients following treatment for colorectal cancer: risk factors for unmet needs and the association between unmet needs and health related quality of life-results from the ColoREctal Wellbeing (CREW) study. Journal of Cancer Survivorship: Research and Practice 13(6):899–909. https://doi.org/10.1007/s11764-019-00805-6CrossRef Sodergren SC, Wheelwright SJ, Permyakova NV, Patel M, Calman L, Smith PWF, Din A, Richardson A, Fenlon D, Winter J, Corner J, Foster C (2019) Supportive care needs of patients following treatment for colorectal cancer: risk factors for unmet needs and the association between unmet needs and health related quality of life-results from the ColoREctal Wellbeing (CREW) study. Journal of Cancer Survivorship: Research and Practice 13(6):899–909. https://​doi.​org/​10.​1007/​s11764-019-00805-6CrossRef
14.
17.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRef
18.
go back to reference Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of Cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579CrossRef Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of Cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579CrossRef
19.
go back to reference Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, Hackl NA, Heading G (2011) Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO 22(10):2179–2190. https://doi.org/10.1093/annonc/mdq721CrossRef Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, Hackl NA, Heading G (2011) Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO 22(10):2179–2190. https://​doi.​org/​10.​1093/​annonc/​mdq721CrossRef
20.
go back to reference Aaronson NK, Mattioli V, Minton O, Weis J, Johansen C, Dalton SO, Verdonck-de Leeuw IM, Stein KD, Alfano CM, Mehnert A, de Boer A, van de Poll-Franse LV (2014) Beyond treatment – psychosocial and behavioural issues in cancer survivorship research and practice. Eur J Cancer Suppl 12(1):54–64CrossRef Aaronson NK, Mattioli V, Minton O, Weis J, Johansen C, Dalton SO, Verdonck-de Leeuw IM, Stein KD, Alfano CM, Mehnert A, de Boer A, van de Poll-Franse LV (2014) Beyond treatment – psychosocial and behavioural issues in cancer survivorship research and practice. Eur J Cancer Suppl 12(1):54–64CrossRef
21.
go back to reference Sarker S-J, Smith SK, Chowdhury K, Ganz PA, Zimmerman S, Gribben J, Korszun A (2017) Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors. Support Care Cancer 25(3):739–748CrossRef Sarker S-J, Smith SK, Chowdhury K, Ganz PA, Zimmerman S, Gribben J, Korszun A (2017) Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors. Support Care Cancer 25(3):739–748CrossRef
23.
go back to reference Groenvold M, Klee MC, Sprangers MAG, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50(4):441–450CrossRef Groenvold M, Klee MC, Sprangers MAG, Aaronson NK (1997) Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. J Clin Epidemiol 50(4):441–450CrossRef
24.
go back to reference Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker J, Stewart-Brown S (2007) The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes 5(1):63CrossRef Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J, Secker J, Stewart-Brown S (2007) The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes 5(1):63CrossRef
25.
go back to reference Crespi CM, Ganz PA, Petersen L, Castillo A, Caan B (2008) Refinement and psychometric evaluation of the impact of cancer scale. JNCI: Journal of the National Cancer Institute 100(21):1530–1541CrossRef Crespi CM, Ganz PA, Petersen L, Castillo A, Caan B (2008) Refinement and psychometric evaluation of the impact of cancer scale. JNCI: Journal of the National Cancer Institute 100(21):1530–1541CrossRef
26.
go back to reference Stanton AL, Bower JE, Low CA (2006) Posttraumatic growth after Cancer. In: Calhoun LG, Tedeschi RG (eds) Handbook of posttraumatic growth: research & practice, p. 138–175. Lawrence Erlbaum Associates Publishers Stanton AL, Bower JE, Low CA (2006) Posttraumatic growth after Cancer. In: Calhoun LG, Tedeschi RG (eds) Handbook of posttraumatic growth: research & practice, p. 138–175. Lawrence Erlbaum Associates Publishers
Metadata
Title
Measuring quality of life in people living with and beyond cancer in the UK
Authors
Elisavet Moschopoulou
Jennifer Deane
Morvwen Duncan
Sharif A. Ismail
Sophie Moriarty
Shah-Jalal Sarker
Peter White
Ania Korszun
on behalf of the SURECAN Development Grant investigators
Publication date
01-10-2021
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-021-06105-z

Other articles of this Issue 10/2021

Supportive Care in Cancer 10/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine